Citation Impact
Citing Papers
In vivo imaging of hydrogen peroxide production in a murine tumor model with a chemoselective bioluminescent reporter
2010 StandoutNobel
Strategy for Dual-Analyte Luciferin Imaging: In Vivo Bioluminescence Detection of Hydrogen Peroxide and Caspase Activity in a Murine Model of Acute Inflammation
2013 StandoutNobel
Receptor for Advanced Glycation End Products Expression on T Cells Contributes to Antigen-Specific Cellular Expansion In Vivo
2007
RAGE: A journey from the complications of diabetes to disorders of the nervous system – striking a fine balance between injury and repair
2005
Oxidative stress and diabetic cardiovascular complications
2005
RAGE Drives the Development of Glomerulosclerosis and Implicates Podocyte Activation in the Pathogenesis of Diabetic Nephropathy
2003
Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.
1998
THE CELLULAR AND MOLECULAR MECHANISMS OF DIABETIC COMPLICATIONS
1996
Apoptosis in the nervous system
2000 StandoutNature
Developmental Control of Blood Cell Migration by the Drosophila VEGF Pathway
2002
Inflammation and metabolic disorders
2006 StandoutNature
FEEL-1 and FEEL-2 Are Endocytic Receptors for Advanced Glycation End Products
2003
Advanced glycation and endothelial functions: A link towards vascular complications in diabetes
2004
Advanced Glycation End Products-Induced Gene Expression of Scavenger Receptors in Cultured Human Monocyte-Derived Macrophages
2000
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
2000 StandoutNature
Scavenger Receptor Class B Type I-mediated Reverse Cholesterol Transport Is Inhibited by Advanced Glycation End Products
2001
Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
1996 Standout
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression
1999
Prospects for Cardiovascular Research
2001 StandoutNobel
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
2002 StandoutNature
Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids.
1996
Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial Cells
1998
Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein
2004
Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases
2000 Nature
Advanced glycosylation end products induced tissue factor expression in human monocyte-like U937 cells and increased tissue factor expression in monocytes from diabetic patients
1998
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
2008
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
2001
Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
2002 StandoutNature
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats.
1996
Regulated portals of entry into the cell
2003 StandoutNature
Angiogenesis in cancer and other diseases
2000 StandoutNature
RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes
2005
Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors
1998
The effect of advanced glycation end-product formation upon cell-matrix interactions
1999
Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products
1997
VEGF Gene Delivery to Muscle
1998
Induction of synthesis and secretion of interleukin 1β in the human monocytic THP-1 cells by human serum albumins modified with methylglyoxal and advanced glycation endproducts
1996
Lymphangiogenesis in development and human disease
2005 StandoutNature
Gene therapy for myocardial angiogenesis
1999
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
1998
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice
2001
Life in extreme environments
2001 StandoutNature
Vascular permeability factor/vascular endothelial growth factor:A multifunctional angiogenic cytokine
1997
Vascular Endothelial Growth Factor: Molecular and Biological Aspects
1999
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
2000
The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis.
1996
Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.
1997
Neurodegeneration and Inflammation
2008
Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide
1995
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
1995
Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin
1998
Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation
2009
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment
2004 Standout
From endoplasmic-reticulum stress to the inflammatory response
2008 StandoutNature
Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress
1997
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis
1995
RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes
2000
Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
1996 Standout
Oxidants, oxidative stress and the biology of ageing
2000 StandoutNature
Vascular-specific growth factors and blood vessel formation
2000 StandoutNature
Caveolae: From Cell Biology to Animal Physiology
2002
Fibulin-5/DANCE is essential for elastogenesis in vivo
2002 StandoutNatureNobel
Atherosclerosis — An Inflammatory Disease
1999 Standout
Inflammation in atherosclerosis
2002 StandoutNature
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes
2004
Blockade of Receptor for Advanced Glycation End-Products Restores Effective Wound Healing in Diabetic Mice
2001
Origin and physiological roles of inflammation
2008 StandoutNature
Biochemistry and molecular cell biology of diabetic complications
2001 StandoutNature
VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells
1999
Sp1-binding Elements in the Promoter of RAGE Are Essential for Amphoterin-mediated Gene Expression in Cultured Neuroblastoma Cells
1998
CED-1 Is a Transmembrane Receptor that Mediates Cell Corpse Engulfment in C. elegans
2001 StandoutNobel
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
1996 StandoutNature
Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy
2005
Atherogenesis and Advanced Glycation: Promotion, Progression, and Preventiona
1997
Renal catabolism of advanced glycation end products: The fate of pentosidine
1998
Atherosclerosis
2000 StandoutNature
Elastin is an essential determinant of arterial morphogenesis
1998 StandoutNature
Synthesis and secretion of tumour necrosis factor-α by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts
1997
The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities
1996
Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation
2006
Angiogenesis as a therapeutic target
2005 StandoutNature
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
1999 Standout
Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways
1999
Molecular mechanisms of ageing in connective tissues
2001
Novel Expression of Vascular Endothelial Growth Factor Receptor (VEGFR)-3 and VEGF-C on Corneal Dendritic Cells
2003
Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia
1999
RAGE Mediates a Novel Proinflammatory Axis
1999 Standout
Arterial Gene Transfer for Therapeutic Angiogenesis in Patients with Peripheral Artery Disease. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts
1996
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
1999 StandoutScience
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products
2004
Molecular Mechanisms of Coronary Collateral Vessel Growth
1996
The Free Radical Theory of Aging Matures
1998 Standout
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins.
1994
Advanced Glycation End Products
2006 Standout
Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations
2000 StandoutNobel
AN APPETITE FOR APOPTOTIC CELLS? CONTROVERSIES AND CHALLENGES
2000
Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins.
1996
Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
2004
Local Delivery of Vascular Endothelial Growth Factor Accelerates Reendothelialization and Attenuates Intimal Hyperplasia in Balloon-Injured Rat Carotid Artery
1995
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins
1994
Glycation, Inflammation, and RAGE
2003
Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
1996
Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus.
1996
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury
2003
The Biology of Vascular Endothelial Growth Factor
1997 Standout
The Pathobiology of Diabetic Complications
2005 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Molecular Therapies for Vascular Diseases
1996 Science
The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins
2003
Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
2008
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins.
1992
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
1999 StandoutScience
Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE
2002
Oxidative Stress and Diabetic Complications
2010 Standout
Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions.
1994
Soluble Vascular Cell Adhesion Molecule-1 as a Biohumoral Correlate of Atherosclerosis
1997
Altered proliferation of retinal microvascular cells on glycated matrix.
1995
Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations
1994
Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.
1997
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
2001
Induction of Macrophage VEGF in Response to Oxidized LDL and VEGF Accumulation in Human Atherosclerotic Lesions
1998
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
HMGB1 and RAGE in Inflammation and Cancer
2010
RAGE: therapeutic target and biomarker of the inflammatory response—the evidence mounts
2009
RAGE Control of Diabetic Nephropathy in a Mouse Model
2006
Activation of Receptor for Advanced Glycation End Products
1999
ADVANCED PROTEIN GLYCOSYLATION IN DIABETES AND AGING
1995
Mechanisms of Diabetic Complications
2013 Standout
Understanding RAGE, the receptor for advanced glycation end products
2005
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
1994
Glucosamine-Induced Endoplasmic Reticulum Dysfunction Is Associated With Accelerated Atherosclerosis in a Hyperglycemic Mouse Model
2006
Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy
2002
Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products
2003
Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products
2004
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.
2000
Endothelial cells in physiology and in the pathophysiology of vascular disorders.
1998 Standout
Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues.
1993
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
1996 StandoutNature
Advanced Glycation End Product (AGE)–Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE
1997
Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
1994
Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells.
2000
Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex
1995
Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells
1997
High Levels of Dietary Advanced Glycation End Products Transform Low-Dersity Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients
2004
Acute Hyperglycemia Causes Intracellular Formation of CML and Activation of ras, p42/44 MAPK, and Nuclear Factor κB in PBMCs
2003
RAGE Axis
2004
Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
2001
Works of A.M. Schmidt being referenced
Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.
1995
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products.
1993
Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes
1993
Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes
1993
The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide
1994
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface.
1992